- Entered into a strategic licensing collaboration with Janssen Pharmaceutica N.V. (Janssen) for two novel oncology assets from Janssen's early development portfolio. TRC253, intended for the treatment of men with prostate cancer, is a Phase 1/2 ready novel small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that may display drug resistance to Xtandi ® (enzalutamide). TRC694, intended for the treatment of patients with hematologic malignancies, including myeloma, is a pre-clinical asset that is a potent, oral inhibitor of NF-kB inducing kinase (NIK).
- Concurrent with the strategic licensing collaboration, Johnson & Johnson Innovation - JJDC, Inc. (JJDC) completed a $5.0 million equity investment in TRACON through the purchase of 840,022 shares of common stock at $5.95 per share determined by the average of the daily volume weighted average closing prices of the common stock as reported on NASDAQ for the five days prior to the date of the purchase.
- Announced the successful completion of an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) and a Protocol Assistance Meeting with the European Medicines Agency (EMA). TRACON reached agreement with both regulatory agencies regarding key elements of the Phase 3 program for TRC105 in angiosarcoma and expects to initiate the Phase 3 study by year-end, following an expected special protocol assessment (SPA) agreement with the FDA.
- Reported updated results from a Phase 1b clinical trial combining TRC105 with Inlyta ® (axitinib) in patients with advanced or metastatic renal cell carcinoma (RCC) at the European Society for Medical Oncology (ESMO) 2016 Congress. Median progression free survival (PFS) of 11.3 months was observed in all RCC patients in the study, including those patients with clear cell RCC, the most prevalent form of RCC. An objective response rate (ORR) of 29% was also seen in the trial. For comparative purposes, median PFS observed in the large subgroup of VEGFR TKI-refractory patients treated with Inlyta (n=194) in the Inlyta AXIS Phase 3 study in second line clear cell RCC patients (a separate trial) was 4.8 months and the ORR was 11.3%.
- Initiated dosing in a global Phase 2 trial of TRC105 in patients with gestational trophoblastic neoplasia, or GTN (including choriocarcinoma). The primary endpoint of the trial is response rate and TRACON expects to enroll a total of 30 patients.
Expected Milestones over Remainder of 2016 or Early 2017
- Updated data on angiosarcoma patients treated with TRC105 in combination with Votrient from the Phase 1b/2 trial will be presented at the Connective Tissue Oncology Society (CTOS) meeting in Lisbon, Portugal on November 11.
- Pre-clinical data for TRACON's endoglin antibodies in models of liver fibrosis and non-alcoholic steatohepatitis (NASH) will be presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting ®) in Boston on November 13.
- Completion of an SPA agreement with the FDA for a global Phase 3 pivotal trial of TRC105 in angiosarcoma.
- Announcement of top-line data from the randomized Phase 2 trial of TRC105 in combination with Avastin ® (bevacizumab) in glioblastoma patients being conducted through the National Cancer Institute Clinical Therapy Evaluation Program (NCI CTEP).
- Cash and cash equivalents were $35.1 million at September 30, 2016, compared to $36.2 million and $52.2 million at June 30, 2016 and December 31, 2015, respectively. The September 30, 2016 balance includes the $5.0 million equity investment from JJDC.
- Collaboration revenue for the third quarter of 2016 was $0.8 million, compared to $1.2 million for the third quarter of 2015.
- Research and development expenses for the third quarter of 2016 were $4.5 million, compared to $5.9 million for the third quarter of 2015. The decrease in 2016 as compared to 2015 primarily resulted from decreased TRC105 drug manufacturing expenses, offset by increased clinical study related expenses and expenses associated with acquiring TRC253 and TRC694.
- General and administrative expenses for the third quarter of 2016 were $1.9 million, compared to $1.5 million for the third quarter of 2015. The increase in 2016 as compared to 2015 was primarily a result of increased compensation related expenses from increased headcount in 2016.
- The net loss for the third quarter of 2016 was $5.9 million, compared to a loss of $6.4 million for the third quarter of 2015.
About TRC105 (carotuximab)TRC105 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php. About TRACON TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company's clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. - TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com. Forward-Looking Statements Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding TRACON's plans to further develop its product candidates, expectations regarding the initiation and timing of future clinical trials by TRACON or third parties, expected development milestones, availability of additional clinical data, and plans to complete an SPA agreement with the FDA. Risks that could cause actual results to differ from those expressed in these forward-looking statements include: risks associated with clinical development; whether TRACON, the NCI or others will be able to complete or initiate clinical trials on TRACON's expected timelines, if at all; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; the fact that TRACON has limited control over whether or when the NCI completes on-going trials or sponsors additional trials of TRACON's product candidates; potential changes in regulatory requirements in the United States and foreign countries; TRACON's reliance on third parties for the development of its product candidates, including the conduct of its clinical trials and manufacture of its product candidates; whether TRACON will be able to obtain additional financing; and other risks described in TRACON's filings with the Securities and Exchange Commission under the heading "Risk Factors". All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. TRACON undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
|TRACON Pharmaceuticals, Inc.|
|Unaudited Condensed Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Research and development||4,531||5,885||16,799||15,121|
|General and administrative||1,881||1,530||5,934||4,019|
|Total operating expenses||6,412||7,415||22,733||19,140|
|Loss from operations||(5,597||)||(6,235||)||(19,901||)||(12,631||)|
|Total other income (expense)||(274||)||(212||)||(793||)||(732||)|
|Accretion to redemption value of redeemable convertible preferred stock||-||-||-||(31||)|
|Net loss attributable to common stockholders||$||(5,871||)||$||(6,447||)||$||(20,694||)||$||(13,394||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.48||)||$||(0.53||)||$||(1.70||)||$||(1.24||)|
|Weighted-average common shares outstanding, basic and diluted||12,227,081||12,117,988||12,200,628||10,761,383|
|TRACON Pharmaceuticals, Inc.|
|Condensed Consolidated Balance Sheets|
|September 30,||December 31,|
|Cash and cash equivalents||$||29,648||$||41,373|
|Prepaid and other assets||1,395||1,150|
|Total current assets||36,508||53,306|
|Property and equipment, net||106||173|
|Liabilities and Stockholders' Equity|
|Accounts payable and accrued expenses||$||6,697||$||8,281|
|Accrued compensation and related expenses||1,188||1,163|
|Current portion of deferred revenue||1,749||3,353|
|Long-term debt, current portion||3,536||1,378|
|Total current liabilities||13,170||14,175|
|Other long-term liabilities||874||905|
|Long-term debt, less current portion||4,786||7,464|
|Commitments and contingencies|
|Additional paid-in capital||97,055||89,556|
|Total stockholders' equity||17,784||30,978|
|Total liabilities and stockholders' equity||$||36,614||$||53,522|
Company Contact:Casey LoganChief Business Officer(858) 550-0780 ext. email@example.comInvestor Contact:Andrew McDonaldLifeSci Advisors LLC646-597-6987Andrew@lifesciadvisors.com